Panichi Vincenzo, Rocchetti Maria Teresa, Scatena Alessia, Rosati Alberto, Migliori Massimiliano, Pizzarelli Francesco, Gesualdo Loreto
Nephrology and Dialysis USL Nord Ovest Toscana, Versilia Hospital, Toscana, Italy.
Department of Emergency and Organ Transplantation, Section of Nephrology, University of Bari 'Aldo Moro', Bari, Italy.
J Nephrol. 2017 Aug;30(4):583-591. doi: 10.1007/s40620-017-0381-2. Epub 2017 Mar 24.
Little information have been provided till now regarding the effect of high volume HDF (hv-OL-HDF) in respect to standard bicarbonate dialysis (BHD) in medium-long term protein-bound toxins removal.
A randomised cross-over multicentre study (REDERT study) was designed to compare the effects of hv-OL-HDF and low-flux BHD on uremic toxins serum levels in 36 chronic dialysis patients followed for 13 months. Group 1 patients were treated with BHD (Treatment A) for 6 months, and afterwards, they were transferred to hv-OL-HDF for a further 6 months (Treatment B). Group 2 patients were treated with Treatment B for 6 months, and afterwards, they were transferred to Treatment A for a further 6 months. Total and free pre-dialysis indoxyl-sulfate (IS) and p-cresyl-sulfate (pCS) were determined starting a midweek dialysis session at baseline and after six months of hv-OL-HDF or BHD. IS and pCS, were simultaneously measured, by liquid chromatography/electrospray ionization-tandem mass spectrometry, Kt/v and pre and post-dialysis b-2microglobulin (b2MG) levels were measured every three months.
Kt/V was significantly increased in hv-OL-HDF (from 1.47 ± 0.24 to 1.49 ± 0.16; p < 0.01) and was reduced in BHD (from 1.51 ± 0.2 to 1.36 ± 0.21; p < 0.001). The mean infusion volume in HDF was 20.9 ± 2.1 L with a mean total convective volume of 23.8 ± 2.3 L and a significant removal of b2MG was obtained in hv-OL-HDF at month 3 and month 6. Both free and total levels of IS and pCS were significantly reduced in hv-OL-HDF at month 6 in respect to BHD.
In the present study we confirm the assumption that post-HDF is an effective technique in small and protein-bound uremic toxins removal.
到目前为止,关于高通量血液透析滤过(hv - OL - HDF)相对于标准碳酸氢盐透析(BHD)在中长期清除蛋白结合毒素方面的效果,所提供的信息较少。
设计了一项随机交叉多中心研究(REDERT研究),以比较hv - OL - HDF和低通量BHD对36例慢性透析患者血清中尿毒症毒素水平的影响,这些患者随访了13个月。第1组患者先接受6个月的BHD治疗(治疗A),之后再接受6个月的hv - OL - HDF治疗(治疗B)。第2组患者先接受6个月的治疗B,之后再接受6个月的治疗A。在基线时以及hv - OL - HDF或BHD治疗6个月后,从周中透析 session开始测定透析前总的和游离的硫酸吲哚酚(IS)和硫酸对甲酚(pCS)。通过液相色谱/电喷雾电离串联质谱法同时测定IS和pCS,每三个月测量一次Kt/v以及透析前和透析后的β2微球蛋白(β2MG)水平。
hv - OL - HDF组的Kt/V显著增加(从1.47±0.24增至1.49±0.16;p < 0.01),而BHD组则降低(从1.51±0.2降至1.36±0.21;p < 0.001)。血液透析滤过的平均输注量为20.9±2.1 L,平均总对流体积为23.8±2.3 L,在hv - OL - HDF治疗的第3个月和第6个月,β2MG有显著清除。与BHD相比,hv - OL - HDF在第6个月时,游离和总的IS及pCS水平均显著降低。
在本研究中,我们证实了这样一个假设,即血液透析滤过后是清除小分子和蛋白结合尿毒症毒素的有效技术。